After Today’s Bullish Options Activity, Is Direxion Daily S&P Biotech Bear 3X Shares’s Near-Term Analysis Positive?

 After Today's Bullish Options Activity, Is Direxion Daily S&P Biotech Bear 3X Shares's Near Term Analysis Positive?

In today’s session Direxion Daily S&P Biotech Bear 3X Shares (LABD) registered an unusually high (350) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious LABD increase. With 350 contracts traded and 7984 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: LABD170120C00015000 closed last at: $3.2 or 33.3% up. The stock decreased 5.57% or $0.86 on November 23, hitting $14.59. Direxion Daily S&P Biotech Bear 3X Shares (NYSEARCA:LABD) has declined 59.13% since April 22, 2016 and is downtrending. It has underperformed by 64.54% the S&P500.

More notable recent Direxion Daily S&P Biotech Bear 3X Shares (NYSEARCA:LABD) news were published by: Marketwatch.com which released: “Direxion Daily S&P Biotech Bear 3X Shares” on March 08, 2014, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on May 29, 2015, Etftrends.com published: “Triple-Leveraged Biotech ETFs Could be Coming Soon” on March 20, 2015. More interesting news about Direxion Daily S&P Biotech Bear 3X Shares (NYSEARCA:LABD) were released by: Investorplace.com and their article: “Be Careful Before Loving Leveraged Biotech ETFs” published on October 06, 2015 as well as Marketwatch.com‘s news article titled: “/quotes/zigman/3870025/realtime” with publication date: July 19, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment